Lumiata

Lumiata | May 26, 2016

Lumiata, the AI-powered predictive analytics company, today announced that it has raised $10 million in financing led by Intel Capital. This latest announcement comes as Lumiata accelerates its deployment of medical artificial intelligence that dramatically improves risk and care management for payers, physicians and population health organizations.All existing investors, including Blue Cross Blue Shield Venture Partners, Sandbox Industries, and Khosla Ventures fully participated in this Series ...

Lumiata | May 26, 2016

Lumiata, a health IT company that enlists predictive analytics tool to zero in on individuals at risk for developing any of a handful of chronic conditions and projecting the trajectory of their risk over time, has raised a $10 million Series B round led by Intel Capital, according to a company statement....

Lumiata | May 26, 2016

The round was led by Intel Capital with participation from existing investors Blue Cross Blue Shield Venture Partners, Sandbox Industries, and Khosla Ventures.The company has raised $20m in total funding.Founded in 2013 by Ash Damle, CEO, Lumiata is a predictive analytics company that leverages medical artificial intelligence to enable health organizations to manage risk and prioritize care.The Lumiata Medical Graph analyzes hundreds of healthcare data sets within the context of clinical practic...

Lumiata | July 29, 2016

The convergence between digital health and pharmaceutical companies has been an interesting trend to witness in the past few years. Increasingly, pharma companies want to move from being customers of digital health companies to having a role in steering their future as investors. So it shouldn’t be surprising that drug developers based in Japan — the second largest market for pharmaceuticals — are also getting involved. Tokyo-based Astellas Pharma has partnered with early stage...